DermBiont’s mission is to become the world’s leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root causes of skin diseases through the development of targeted small molecule therapeutics with well-defined mechanisms of action and biotherapeutics that repair an imbalance of the microbiome. The company’s targeted topical therapeutics pipeline includes SM-020 for the treatment of seborrheic keratosis, SM-030 for the treatment of hyperpigmentation disorders of the skin, and DBI-001 & DBI-002 for the treatment of atopic dermatitis, tinea pedis, and onychomycosis. For more information, please visit www.dermbiont.com.
View Top Employees from DermBiont, Inc.Website | http://www.dermbiont.com |
Revenue | $4 million |
Funding | $8.2 million |
Employees | 39 (39 on RocketReach) |
Founded | 2017 |
Address | 451 D St Suite 908, Boston, Massachusetts 02210, US |
Phone | (781) 929-5098 |
Technologies |
JavaScript,
HTML,
Twitter
+14 more
(view full list)
|
Industry | Biotechnology Research, Medical Testing & Clinical Laboratories, Biotechnology, Healthcare, Science and Engineering, Health Care, Medical, Therapeutics |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular DermBiont, Inc. employee's phone or email?
The DermBiont, Inc. annual revenue was $4 million in 2024.
Robert Brucker is the Co-founder and Chief Scientific Officer of DermBiont, Inc..
39 people are employed at DermBiont, Inc..
DermBiont, Inc. is based in Boston, Massachusetts.
The NAICS codes for DermBiont, Inc. are [54171, 54, 541714, 541, 5417].
The SIC codes for DermBiont, Inc. are [87, 873].